To test this hypothesis, TIGIT function was blocked in vitro using Tiragolumab, an antagonistic anti-TIGIT monoclonal antibody currently under evaluation in a large number of clinical trials in cancer patients in combination with the anti-PD-L1 mAb Atezolizumab (55). The gene discussed is TIGIT; the disease is cancer.